Mercer Global Advisors
FATE icon

Mercer Global Advisors’s Fate Therapeutics FATE Stock Holding History

Mercer Global Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306K Buy
113,380
+63,576
+128% +$118K ﹤0.01% 2784
2026
Q1 		$59.8K Buy
49,804
+35,886
+258% +$43.7K ﹤0.01% 3109
2025
Q4 		$13.7K Sell
13,918
-2,459
-15% -$2.95K ﹤0.01% 2831
2025
Q3 		$20.6K Buy
+16,377
New +$17.7K ﹤0.01% 2617

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Mercer Global Advisors's FATE Position: Q2 2026 in Review

Mercer Global Advisors increased its Fate Therapeutics (FATE) stake by 128% in Q2 2026, buying an estimated $118K and bringing the position to 113,380 shares worth $306K. The position accounts for ﹤0.01% of the portfolio, ranked #2784.

Mercer Global Advisors first reported a position in FATE in Q3 2025 and has held it in 4 quarters since. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Mercer Global Advisors held 113,380 shares of Fate Therapeutics worth $306K as of Q2 2026.
  • Mercer Global Advisors bought 63,576 Fate Therapeutics shares in Q2 2026, an estimated $118K.
  • Fate Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2784 holding.
  • Mercer Global Advisors first reported a position in Fate Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.